Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial ; volume:16 ; number:1 ; day:29 ; month:5 ; year:2016 ; pages:1-8 ; date:12.2016
BMC psychiatry ; 16, Heft 1 (29.5.2016), 1-8, 12.2016
- Urheber
-
Takekita, Yoshiteru
- Beteiligte Personen und Organisationen
-
Koshikawa, Yosuke
Fabbri, Chiara
Sakai, Shiho
Sunada, Naotaka
Onohara, Ai
Nishida, Keiichiro
Yoshimura, Masafumi
Kato, Masaki
Serretti, Alessandro
Kinoshita, Toshihiko
SpringerLink (Online service)
- DOI
-
10.1186/s12888-016-0883-9
- URN
-
urn:nbn:de:1111-201606018445
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Takekita, Yoshiteru
- Koshikawa, Yosuke
- Fabbri, Chiara
- Sakai, Shiho
- Sunada, Naotaka
- Onohara, Ai
- Nishida, Keiichiro
- Yoshimura, Masafumi
- Kato, Masaki
- Serretti, Alessandro
- Kinoshita, Toshihiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-Acting Reversible Contraception
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Development of long-acting ARV’s
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-Acting Reversible Contraception
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Development of long-acting ARV’s
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
A health economics study of long-acting injectable once-monthly paliperidone palmitate in schizophrenia: a one-year mirror-image study in China
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-Acting Reversible Contraception
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Development of long-acting ARV’s
Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies
Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia